PMC:7228307 / 37442-37807 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"635","span":{"begin":29,"end":33},"obj":"Gene"}],"attributes":[{"id":"A635","pred":"tao:has_database_id","subj":"635","obj":"Gene:3502"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"It should also be noted that IgG3 has not been used in therapeutic mAbs despite its unique biology. The main impediment to its use are its physicochemical properties such as susceptibility to proteolysis and propensity to aggregate that present challenges to industry‐scale production and stability but protein engineering is attempting to overcome these hurdles.73"}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T339","span":{"begin":303,"end":310},"obj":"Body_part"}],"attributes":[{"id":"A339","pred":"fma_id","subj":"T339","obj":"http://purl.org/sig/ont/fma/fma67257"}],"text":"It should also be noted that IgG3 has not been used in therapeutic mAbs despite its unique biology. The main impediment to its use are its physicochemical properties such as susceptibility to proteolysis and propensity to aggregate that present challenges to industry‐scale production and stability but protein engineering is attempting to overcome these hurdles.73"}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T20","span":{"begin":268,"end":273},"obj":"Body_part"}],"attributes":[{"id":"A20","pred":"uberon_id","subj":"T20","obj":"http://purl.obolibrary.org/obo/UBERON_0002542"}],"text":"It should also be noted that IgG3 has not been used in therapeutic mAbs despite its unique biology. The main impediment to its use are its physicochemical properties such as susceptibility to proteolysis and propensity to aggregate that present challenges to industry‐scale production and stability but protein engineering is attempting to overcome these hurdles.73"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T690","span":{"begin":34,"end":37},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"}],"text":"It should also be noted that IgG3 has not been used in therapeutic mAbs despite its unique biology. The main impediment to its use are its physicochemical properties such as susceptibility to proteolysis and propensity to aggregate that present challenges to industry‐scale production and stability but protein engineering is attempting to overcome these hurdles.73"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T203","span":{"begin":303,"end":310},"obj":"Chemical"}],"attributes":[{"id":"A203","pred":"chebi_id","subj":"T203","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"}],"text":"It should also be noted that IgG3 has not been used in therapeutic mAbs despite its unique biology. The main impediment to its use are its physicochemical properties such as susceptibility to proteolysis and propensity to aggregate that present challenges to industry‐scale production and stability but protein engineering is attempting to overcome these hurdles.73"}

{"project":"LitCovid-sample-PD-IDO","denotations":[{"id":"T197","span":{"begin":174,"end":188},"obj":"http://purl.obolibrary.org/obo/IDO_0000467"},{"id":"T198","span":{"begin":274,"end":284},"obj":"http://purl.obolibrary.org/obo/IDO_0000607"}],"text":"It should also be noted that IgG3 has not been used in therapeutic mAbs despite its unique biology. The main impediment to its use are its physicochemical properties such as susceptibility to proteolysis and propensity to aggregate that present challenges to industry‐scale production and stability but protein engineering is attempting to overcome these hurdles.73"}

{"project":"LitCovid-sample-CHEBI","denotations":[{"id":"T45","span":{"begin":303,"end":310},"obj":"Chemical"}],"attributes":[{"id":"A45","pred":"chebi_id","subj":"T45","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"}],"text":"It should also be noted that IgG3 has not been used in therapeutic mAbs despite its unique biology. The main impediment to its use are its physicochemical properties such as susceptibility to proteolysis and propensity to aggregate that present challenges to industry‐scale production and stability but protein engineering is attempting to overcome these hurdles.73"}

{"project":"LitCovid-sample-Pubtator","denotations":[{"id":"635","span":{"begin":29,"end":33},"obj":"Gene"}],"attributes":[{"id":"A635","pred":"pubann:denotes","subj":"635","obj":"Gene:3502"}],"text":"It should also be noted that IgG3 has not been used in therapeutic mAbs despite its unique biology. The main impediment to its use are its physicochemical properties such as susceptibility to proteolysis and propensity to aggregate that present challenges to industry‐scale production and stability but protein engineering is attempting to overcome these hurdles.73"}

{"project":"LitCovid-sample-sentences","denotations":[{"id":"T212","span":{"begin":0,"end":99},"obj":"Sentence"},{"id":"T213","span":{"begin":100,"end":365},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"It should also be noted that IgG3 has not been used in therapeutic mAbs despite its unique biology. The main impediment to its use are its physicochemical properties such as susceptibility to proteolysis and propensity to aggregate that present challenges to industry‐scale production and stability but protein engineering is attempting to overcome these hurdles.73"}

{"project":"LitCovid-sample-PD-UBERON","denotations":[{"id":"T20","span":{"begin":268,"end":273},"obj":"Body_part"}],"attributes":[{"id":"A20","pred":"uberon_id","subj":"T20","obj":"http://purl.obolibrary.org/obo/UBERON_0002542"}],"text":"It should also be noted that IgG3 has not been used in therapeutic mAbs despite its unique biology. The main impediment to its use are its physicochemical properties such as susceptibility to proteolysis and propensity to aggregate that present challenges to industry‐scale production and stability but protein engineering is attempting to overcome these hurdles.73"}

{"project":"LitCovid-sample-PD-FMA","denotations":[{"id":"T338","span":{"begin":303,"end":310},"obj":"Body_part"}],"attributes":[{"id":"A338","pred":"fma_id","subj":"T338","obj":"http://purl.org/sig/ont/fma/fma67257"}],"text":"It should also be noted that IgG3 has not been used in therapeutic mAbs despite its unique biology. The main impediment to its use are its physicochemical properties such as susceptibility to proteolysis and propensity to aggregate that present challenges to industry‐scale production and stability but protein engineering is attempting to overcome these hurdles.73"}

{"project":"LitCovid-sample-PD-GO-BP-0","denotations":[{"id":"T93","span":{"begin":192,"end":203},"obj":"http://purl.obolibrary.org/obo/GO_0006508"}],"text":"It should also be noted that IgG3 has not been used in therapeutic mAbs despite its unique biology. The main impediment to its use are its physicochemical properties such as susceptibility to proteolysis and propensity to aggregate that present challenges to industry‐scale production and stability but protein engineering is attempting to overcome these hurdles.73"}

{"project":"LitCovid-sample-GO-BP","denotations":[{"id":"T94","span":{"begin":192,"end":203},"obj":"http://purl.obolibrary.org/obo/GO_0006508"}],"text":"It should also be noted that IgG3 has not been used in therapeutic mAbs despite its unique biology. The main impediment to its use are its physicochemical properties such as susceptibility to proteolysis and propensity to aggregate that present challenges to industry‐scale production and stability but protein engineering is attempting to overcome these hurdles.73"}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T94","span":{"begin":192,"end":203},"obj":"http://purl.obolibrary.org/obo/GO_0006508"}],"text":"It should also be noted that IgG3 has not been used in therapeutic mAbs despite its unique biology. The main impediment to its use are its physicochemical properties such as susceptibility to proteolysis and propensity to aggregate that present challenges to industry‐scale production and stability but protein engineering is attempting to overcome these hurdles.73"}

{"project":"LitCovid-sentences","denotations":[{"id":"T212","span":{"begin":0,"end":99},"obj":"Sentence"},{"id":"T213","span":{"begin":100,"end":365},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"It should also be noted that IgG3 has not been used in therapeutic mAbs despite its unique biology. The main impediment to its use are its physicochemical properties such as susceptibility to proteolysis and propensity to aggregate that present challenges to industry‐scale production and stability but protein engineering is attempting to overcome these hurdles.73"}